IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: A report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

Clinical Cancer Research

Volumn 16, Issue 5, 2010, Pages 1597-1604

  Van Den Bent, Martin J ^a   Dubbink, Hendrikus J ^a   Marie, Yannick ^b   Brandes, Alba A ^c   Taphoorn, Martin J B ^d,e   Wesseling, Pieter ^f   Frenay, Marc ^g   Tijssen, Cees C ^h   Lacombe, Denis ⁱ   Idbaih, Ahmed ^b   Van Marion, Ronald ^a   Kros, Johan M ^a   Dinjens, Winand N M ^a   Gorlia, Thierry ⁱ   Sanson, Marc ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c BELLARIA HOSPITAL   (Italy)

^d MC Haaglanden ^*  (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g CENTRE ANTOINE LACASSAGNE   (France)

^h CPRLab   (Netherlands)

ⁱ EORTC DATA CENTER   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; UNCLASSIFIED DRUG; VINCRISTINE;

ADJUVANT THERAPY; ADULT; ANAPLASTIC OLIGODENDROGLIOMA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME 10; CHROMOSOME 10Q; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME 7; CHROMOSOME DELETION; CHROMOSOME LOSS; CLINICAL FEATURE; CODON; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; METHYLATION; MULTIPLE CYCLE TREATMENT; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NECROSIS; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GENES, ERBB-1; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIERS ESTIMATE; LOMUSTINE; MALE; MIDDLE AGED; MUTATION; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; PROCARBAZINE; PROGNOSIS; PROMOTER REGIONS, GENETIC; RADIOTHERAPY; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS; VINCRISTINE; YOUNG ADULT;

EID: 77649122144     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2902     Document Type: Article

References (24)

1. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von DA. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008;116:597-602.
2. Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 2009;11:341-7.
3. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-73.
4. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 2009;118:469-74.
5. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009;27:4150-4.
6. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009;174:1149-53.
7. Bleeker FE, Lamba S, Leenstra S, et al. IDH1 mutations at residue p R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 2009;30:7-11.
8. Kang MR, Kim MS, Oh JE, et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 2009; 125:353-5.
9. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361:1058-66.
10. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739-44.
11. Aghili M, Zahedi F, Rafiee E. Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. J Neurooncol 2009; 91:233-6.
12. Moroni I, Bugiani M, D'Incerti L, et al. L-2-hydroxyglutaric aciduria and brain malignant tumors: a predisposing condition? Neurology 2004;62:1882-4.
13. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant PCV improves progression free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized EORTC phase III trial. J Clin Oncol 2006;24:2715-22.
14. Kouwenhoven MC, Gorlia T, Kros JM, et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro Oncol 2009;11: 737-46.
15. Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumours of the central nervous system. Berlin Heidelberg New York: Springer-Verlag; 1993.
16. van der Sijp, Jr., van Meerbeeck JP, Maat AP, et al. Determination of the molecular relationship between multiple tumors within one patient is of clinical importance. J Clin Oncol 2002;20:1105-14.
17. van den Bent MJ, Dubbink HJ, Sanson M, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 2009; 27:5881-6.
18. Jeuken JW, Cornelissen SJ, Vriezen M, et al. MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 2007;87:1055-65.
19. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Nervous System. 2008.
20. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase iii trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009;27:5874-80.
21. Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol 2006;24:4746-53.
22. Möllemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G. Frequent promotor hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2004;113:379-85.
23. Maintz D, Fiedler K, Koopmann J, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997; 56:1098-104.
24. Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology, 93-1792-1795.